Well-know drugmaker Sun Pharmaceutical Industries Limited has launched its version of COVID-19 anti-viral Favipiravir, branded as FluGuard (Favipiravir 200 mg) in India. It’s priced at Rs. 35 per tablet, which can be used for the treatment of mild to moderate cases of Covid-19.
Notably, Favipiravir was originally developed by Japan’s Fujifilm Holdings Corp under the brand name Avigan for treating influenza. According to the company, It is the only oral anti-viral treatment approved in India for mild to moderate Covid-19 patients.
Meanwhile, commenting on the launch Kirti Ganorkar, CEO of India Business of Sun Pharma, said,
“With over 50,000 Covid-19 cases being reported daily in India, there is an urgent need to provide more treatment options to healthcare professionals. We are launching FluGuard at an economical price to make the drug accessible to more and more patients thereby reducing their financial burden. This is in line with our continuous efforts to support India’s pandemic response.”
This development comes when over 50,000 COVID-19 cases started being reported daily in India. And along with this launch company also announced that they will work closely with the government and medical community to ensure the availability of FluGuard.
And during the same time, as per BSE data, shares of Sun Pharmaceutical Industries closed at Rs 528.50 per scrip, which is clearly up 1.67 percent from its previous close.